文献速递关节外科

商用抗生素骨水泥与骨水泥型初次全膝关节置换术后感染风险

Commercially Prepared Antibiotic-Loaded Bone Cement and Infection Risk Following Cemented Primary Total Knee Arthroplasty.
PubMed 文献 · J Bone Joint Surg Am · 2020-01-01

基于Kaiser Permanente全关节置换登记系统2008至2016年87,018例骨水泥型初次全膝关节置换术,采用倾向评分加权Cox比例风险模型分析。普通骨水泥在感染风险方面非劣于抗生素骨水泥(HR 1.14;95%CI 0.93-1.40),但糖尿病患者使用抗生素骨水泥感染风险更低(HR 0.72;95%CI 0.52-0.99)。作者认为对所有患者常规使用商用抗生素骨水泥的额外成本不合理,需进一步研究其他高危人群。

要点

  • 普通骨水泥在感染风险方面非劣于抗生素骨水泥(HR 1.14;95%CI 0.93-1.40)。
  • 糖尿病患者使用抗生素骨水泥感染风险更低(HR 0.72;95%CI 0.52-0.99)。
  • 抗生素骨水泥与普通骨水泥在翻修风险上无差异证据。

核心结论

  • 作者认为在所有初次全膝关节置换术患者中使用商用抗生素骨水泥的额外成本不合理。
  • 糖尿病患者接受抗生素骨水泥者感染风险降低。
  • 需进一步研究以明确抗生素骨水泥在其他高危人群中的效果。

研究设计与样本

  • 利用Kaiser Permanente全关节置换登记系统评估2008至2016年87,018例骨水泥型初次全膝关节置换术。
  • 主要结局为感染时间(90天深部感染或感染性翻修),采用倾向评分加权Cox比例风险模型进行优效性和非劣效性检验。
  • 对3个高危亚组(糖尿病、体重指数≥35 kg/m²、美国麻醉医师协会分级≥3)分别重复所有分析。
  • 次要翻修结局采用倾向评分加权Cox比例风险模型分析。

主要发现

  • 在所有全膝关节置换术患者中,普通骨水泥在感染风险方面非劣于抗生素骨水泥(HR 1.14;95%CI 0.93-1.40)。
  • 在糖尿病患者中,抗生素骨水泥组感染风险低于普通骨水泥组(HR 0.72;95%CI 0.52-0.99)。
  • 抗生素骨水泥与普通骨水泥相比,翻修风险无差异证据。

局限性

  • 需进一步研究以明确抗生素骨水泥在其他高危人群中的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of commercially available antibiotic-loaded bone cement (ABC) in preventing infection in total knee arthroplasty (TKA) is unclear. We sought to determine the effectiveness of commercially available ABC in reducing the risk of infection following TKA, both overall and among 3 subgroups of patients with a higher risk of infection (diabetes, body mass index ≥35 kg/m, and American Society of Anesthesiologists classification ≥3), and to evaluate the association between the use of ABC and the risks of aseptic revision and revision for aseptic loosening. METHODS: The Kaiser Permanente Total Joint Replacement Registry was utilized to evaluate 87,018 primary cemented TKAs performed from 2008 to 2016. The primary outcome was time to infection (90-day deep infection or septic revision). Reduced infection risk with ABC relative to regular cement was tested with use of propensity-score-weighted Cox proportional-hazards models with superiority and noninferiority testing. All analyses were replicated for each of the 3 high-risk subgroups. For the secondary revision outcomes, propensity-score-weighted Cox proportional-hazards models were utilized. RESULTS: Regular cement was found to be noninferior to ABC with respect to risk infection (hazard ratio [HR], 1.14; 95% confidence interval [CI], 0.93 to 1.40) and cost across all TKA patients. However, a lower risk of infection was observed with ABC among TKA patients with diabetes (HR, 0.72; 95% CI, 0.52 to 0.99). There was no evidence of a difference in risk of revision for ABC compared with regular cement. CONCLUSIONS: We found that the additional cost associated with the use of commercially prepared ABC in primary TKA was not justified in all patients; however, the risk of reduction was lower among patients with diabetes who received ABC. Further study is warranted to identify the efficacy of ABC among other high-risk populations. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Namba RS, Prentice HA, Paxton EW, et al. Commercially Prepared Antibiotic-Loaded Bone Cement and Infection Risk Following Cemented Primary Total Knee Arthroplasty. J Bone Joint Surg Am. 2020. PMID: 32826555. doi:10.2106/JBJS.19.01440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。